EXECUTIVE ENGAGEMENTS
OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
* Login for a full stack data experience
DATE
JUL 2020
TABLES
74
PAGES
146
EDITION
8
PRICE
USD $4950
China Has Risen Into An Economic Powerhouse.
Find Out How You Can Leverage This Opportunity!
SELECT PLAYERS
AstraZeneca PLC; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche AG; Fortress Biotech, Inc.; Immutep Ltd.; Merck & Co., Inc.; Merck KGaA; Novartis International AG; Pfizer, Inc.
SEGMENTS
» Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, Other Applications) » Drug Class (CLTA-4 Inhibitors, PD-1, PD-L1 Inhibitors)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
KEY DIFFERENTIATORS
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
INSIDER ACCESS PRIVILEGES
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Global Competitor Market Shares |
Immune Checkpoint Inhibitors Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
4. GLOBAL MARKET PERSPECTIVE |
Immune Checkpoint Inhibitors Global Market Estimates and Forecasts in US$ Million by Region/Country: 2020-2027 |
Immune Checkpoint Inhibitors Market Share Shift across Key Geographies Worldwide: 2020 VS 2027 |
CLTA-4 Inhibitors (Drug Class) World Market by Region/Country in US$ Million: 2020 to 2027 |
CLTA-4 Inhibitors (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2020 VS 2027 |
PD-1 (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2020 to 2027 |
PD-1 (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2020 VS 2027 |
PD-L1 Inhibitors (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2020 to 2027 |
PD-L1 Inhibitors (Drug Class) Market Share Distribution in Percentage by Region/Country: 2020 VS 2027 |
Lung Cancer (Application) Demand Potential Worldwide in US$ Million by Region/Country: 2020-2027 |
Lung Cancer (Application) Share Breakdown Review by Region/Country: 2020 VS 2027 |
Bladder Cancer (Application) Worldwide Latent Demand Forecasts in US$ Million by Region/Country: 2020-2027 |
Bladder Cancer (Application) Distribution of Global Sales by Region/Country: 2020 VS 2027 |
Melanoma (Application) Sales Estimates and Forecasts in US$ Million by Region/Country for the Years 2020 through 2027 |
Melanoma (Application) Global Market Share Distribution by Region/Country for 2020 and 2027 |
Hodgkin lymphoma (Application) Global Opportunity Assessment in US$ Million by Region/Country: 2020-2027 |
Hodgkin lymphoma (Application) Percentage Share Breakdown of Global Sales by Region/Country: 2020 VS 2027 |
Other Applications (Application) Worldwide Sales in US$ Million by Region/Country: 2020-2027 |
Other Applications (Application) Market Share Shift across Key Geographies: 2020 VS 2027 |
III. MARKET ANALYSIS |
GEOGRAPHIC MARKET ANALYSIS |
UNITED STATES |
Market Facts & Figures |
US Immune Checkpoint Inhibitors Market Share (in %) by Company: 2019 & 2025 |
United States Immune Checkpoint Inhibitors Market Estimates and Projections in US$ Million by Drug Class: 2020 to 2027 |
United States Immune Checkpoint Inhibitors Market Share Breakdown by Drug Class: 2020 VS 2027 |
United States Immune Checkpoint Inhibitors Latent Demand Forecasts in US$ Million by Application: 2020 to 2027 |
Immune Checkpoint Inhibitors Market Share Breakdown in the United States by Application: 2020 VS 2027 |
CANADA |
Canadian Immune Checkpoint Inhibitors Market Estimates and Forecasts in US$ Million by Drug Class: 2020 to 2027 |
Immune Checkpoint Inhibitors Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2020 and 2027 |
Canadian Immune Checkpoint Inhibitors Market Quantitative Demand Analysis in US$ Million by Application: 2020 to 2027 |
Canadian Immune Checkpoint Inhibitors Market Share Analysis by Application: 2020 VS 2027 |
JAPAN |
Japanese Market for Immune Checkpoint Inhibitors: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2020-2027 |
Japanese Immune Checkpoint Inhibitors Market Share Analysis by Drug Class: 2020 VS 2027 |
Japanese Demand Estimates and Forecasts for Immune Checkpoint Inhibitors in US$ Million by Application: 2020 to 2027 |
Immune Checkpoint Inhibitors Market Share Shift in Japan by Application: 2020 VS 2027 |
CHINA |
Chinese Immune Checkpoint Inhibitors Market Growth Prospects in US$ Million by Drug Class for the Period 2020-2027 |
Chinese Immune Checkpoint Inhibitors Market by Drug Class: Percentage Breakdown of Sales for 2020 and 2027 |
Chinese Demand for Immune Checkpoint Inhibitors in US$ Million by Application: 2020 to 2027 |
Chinese Immune Checkpoint Inhibitors Market Share Breakdown by Application: 2020 VS 2027 |
EUROPE |
Market Facts & Figures |
European Immune Checkpoint Inhibitors Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
European Immune Checkpoint Inhibitors Market Demand Scenario in US$ Million by Region/Country: 2018-2025 |
European Immune Checkpoint Inhibitors Market Share Shift by Region/Country: 2020 VS 2027 |
European Immune Checkpoint Inhibitors Market Estimates and Forecasts in US$ Million by Drug Class: 2020-2027 |
European Immune Checkpoint Inhibitors Market Share Breakdown by Drug Class: 2020 VS 2027 |
European Immune Checkpoint Inhibitors Addressable Market Opportunity in US$ Million by Application: 2020-2027 |
European Immune Checkpoint Inhibitors Market Share Analysis by Application: 2020 VS 2027 |
FRANCE |
Immune Checkpoint Inhibitors Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2020-2027 |
French Immune Checkpoint Inhibitors Market Share Analysis by Drug Class: 2020 VS 2027 |
Immune Checkpoint Inhibitors Quantitative Demand Analysis in France in US$ Million by Application: 2020-2027 |
French Immune Checkpoint Inhibitors Market Share Analysis: A 7-Year Perspective by Application for 2020 and 2027 |
GERMANY |
Immune Checkpoint Inhibitors Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2020-2027 |
German Immune Checkpoint Inhibitors Market Share Breakdown by Drug Class: 2020 VS 2027 |
Immune Checkpoint Inhibitors Market in Germany: Annual Sales Estimates and Forecasts in US$ Million by Application for the Period 2020-2027 |
Immune Checkpoint Inhibitors Market Share Distribution in Germany by Application: 2020 VS 2027 |
ITALY |
Italian Immune Checkpoint Inhibitors Market Growth Prospects in US$ Million by Drug Class for the Period 2020-2027 |
Italian Immune Checkpoint Inhibitors Market by Drug Class: Percentage Breakdown of Sales for 2020 and 2027 |
Italian Demand for Immune Checkpoint Inhibitors in US$ Million by Application: 2020 to 2027 |
Italian Immune Checkpoint Inhibitors Market Share Breakdown by Application: 2020 VS 2027 |
UNITED KINGDOM |
United Kingdom Market for Immune Checkpoint Inhibitors: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2020-2027 |
United Kingdom Immune Checkpoint Inhibitors Market Share Analysis by Drug Class: 2020 VS 2027 |
United Kingdom Demand Estimates and Forecasts for Immune Checkpoint Inhibitors in US$ Million by Application: 2020 to 2027 |
Immune Checkpoint Inhibitors Market Share Shift in the United Kingdom by Application: 2020 VS 2027 |
REST OF EUROPE |
Rest of Europe Immune Checkpoint Inhibitors Market Estimates and Forecasts in US$ Million by Drug Class: 2020-2027 |
Rest of Europe Immune Checkpoint Inhibitors Market Share Breakdown by Drug Class: 2020 VS 2027 |
Rest of Europe Immune Checkpoint Inhibitors Addressable Market Opportunity in US$ Million by Application: 2020-2027 |
Rest of Europe Immune Checkpoint Inhibitors Market Share Analysis by Application: 2020 VS 2027 |
ASIA-PACIFIC |
Immune Checkpoint Inhibitors Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2020-2027 |
Asia-Pacific Immune Checkpoint Inhibitors Market Share Analysis by Drug Class: 2020 VS 2027 |
Immune Checkpoint Inhibitors Quantitative Demand Analysis in Asia-Pacific in US$ Million by Application: 2020-2027 |
Asia-Pacific Immune Checkpoint Inhibitors Market Share Analysis: A 7-Year Perspective by Application for 2020 and 2027 |
REST OF WORLD |
Rest of World Immune Checkpoint Inhibitors Market Estimates and Forecasts in US$ Million by Drug Class: 2020 to 2027 |
Immune Checkpoint Inhibitors Market in Rest of World: Percentage Share Breakdown of Sales by Drug Class for 2020 and 2027 |
Rest of World Immune Checkpoint Inhibitors Market Quantitative Demand Analysis in US$ Million by Application: 2020 to 2027 |
Rest of World Immune Checkpoint Inhibitors Market Share Analysis by Application: 2020 VS 2027 |
IV. COMPETITION |
Total Companies Profiled : 42 Click here to request a full table of contents and more details on this project. |
V. CURATED RESEARCH |
KEY DIFFERENTIATORS
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.